{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:27:31Z","timestamp":1793975251128,"version":"4.8.0"},"reference-count":38,"publisher":"American Diabetes Association","issue":"11","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>Randomized controlled trials have shown kidney-protective effects of sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested that these effects translate to clinical practice. However, long-term efficacy, as well as whether the presence or absence of proteinuria and the rate of estimated glomerular filtration rates (eGFR) decline prior to SGLT2 inhibitor initiation modify treatment efficacy among type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) patients, is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Using the Japan Chronic Kidney Disease Database (J-CKD-DB), a nationwide multicenter CKD registry, we developed propensity scores for SGLT2 inhibitor initiation, with 1:1 matching with patients who were initiated on other glucose-lowering drugs. The primary outcome included rate of eGFR decline, and the secondary outcomes included a composite outcome of 50% eGFR decline or end-stage kidney disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>At baseline, mean age at initiation of the SGLT2 inhibitor (n = 1,033) or other glucose-lowering drug (n = 1,033) was 64.4 years, mean eGFR was 68.1 mL\/min per 1.73 m2, and proteinuria was apparent in 578 (28.0%) of included patients. During follow-up, SGLT2 inhibitor initiation was associated with reduced eGFR decline (difference in slope for SGLT2 inhibitors vs. other drugs 0.75 mL\/min\/1.73 m2 per year [0.51 to 1.00]). During a mean follow-up of 24 months, 103 composite kidney outcomes occurred: 30 (14 events per 1,000 patient-years) among the SGLT2 inhibitors group and 73 (36 events per 1,000 patient-years) among the other drugs group (hazard ratio 0.40, 95% CI 0.26\u20130.61). The benefit provided by SGLT2 inhibitors was consistent irrespective of proteinuria and rate of eGFR decline before initiation of SGLT2 inhibitors (Pheterogeneity \u2265 0.35).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>The benefits of SGLT2 inhibitors on kidney function as observed in clinical trials translate to patients treated in clinical practice with no evidence that the effects are modified by the underlying rate of kidney function decline or the presence of proteinuria.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc21-1081","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T22:10:24Z","timestamp":1633039824000},"page":"2542-2551","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":96,"title":["Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database"],"prefix":"10.2337","volume":"44","author":[{"given":"Hajime","family":"Nagasu","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2565-7290","authenticated-orcid":false,"given":"Yuichiro","family":"Yano","sequence":"additional","affiliation":[{"name":"Center for Novel and Exploratory Clinical Trials, Yokohama City University, Kanagawa, Japan"},{"name":"Department of Family Medicine and Community Health, Duke University, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kanegae","sequence":"additional","affiliation":[{"name":"Genki Plaza Medical Center for Health Care, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health, University of New South Wales, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Hirakawa","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Sugawara","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, University of Tokyo Graduate School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Nephrology, Pulmonology and Neurology, Department of Internal Medicine, Asahikawa Medical University, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Tani","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics and Hospital Management, Asahikawa Medical University, Hokkaido, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1468-5170","authenticated-orcid":false,"given":"Jun","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Human Resource Development of Dialysis Therapy for Kidney Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nara Medical University, Nara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Nagoya University Graduate School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiro","family":"Yamagata","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kochi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shigematsu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Rinku General Medical Center, Oosaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sofue","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Dialysis, Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Faculty of Medicine, Shimane University, Shimane, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, Saitama Medical University, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nakashima","sequence":"additional","affiliation":[{"name":"Medical Information Center, Kyushu University Hospital, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Faculty of Health Science and Technology, Kawasaki University of Medical Welfare, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ohe","sequence":"additional","affiliation":[{"name":"Department of Healthcare Information Management, The University of Tokyo Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Okada","sequence":"additional","affiliation":[{"name":"Institute of Health Data Infrastructure for All, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Itano","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Kagawa University, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichiro","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Kawasaki Medical School, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-8102","authenticated-orcid":false,"given":"Kohjiro","family":"Ueki","sequence":"additional","affiliation":[{"name":"Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"2022031309340208900_B1","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"2022031309340208900_B2","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031309340208900_B3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"2022031309340208900_B4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031309340208900_B5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagli flozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031309340208900_B6","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031309340208900_B7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2022031309340208900_B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031309340208900_B9","doi-asserted-by":"crossref","first-page":"m1186","DOI":"10.1136\/bmj.m1186","article-title":"Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study","volume":"369","author":"Pasternak","year":"2020","journal-title":"BMJ"},{"key":"2022031309340208900_B10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(11)60178-5","article-title":"Chronic kidney disease","volume":"379","author":"Levey","year":"2012","journal-title":"Lancet"},{"key":"2022031309340208900_B11","doi-asserted-by":"crossref","first-page":"7351","DOI":"10.1038\/s41598-020-64123-z","article-title":"J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan","volume":"10","author":"Nakagawa","year":"2020","journal-title":"Sci Rep"},{"key":"2022031309340208900_B12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3414\/ME10-01-0015","article-title":"SS-MIX: a ministry project to promote standardized healthcare information exchange","volume":"50","author":"Kimura","year":"2011","journal-title":"Methods Inf Med"},{"key":"2022031309340208900_B13","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s13340-017-0326-y","article-title":"Design of and rationale for the Japan Diabetes compREhensive database project based on an Advanced electronic Medical record System (J-DREAMS)","volume":"8","author":"Sugiyama","year":"2017","journal-title":"Diabetol Int"},{"key":"2022031309340208900_B14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1197\/jamia.M3299","article-title":"Development of an electronic public health case report using HL7 v2.5 to meet public health needs","volume":"17","author":"Rajeev","year":"2010","journal-title":"J Am Med Inform Assoc"},{"key":"2022031309340208900_B15","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.2196\/medinform.5275","article-title":"A querying method over RDF-ized health level seven v2.5 messages using life science knowledge resources","volume":"4","author":"Kawazoe","year":"2016","journal-title":"JMIR Med Inform"},{"key":"2022031309340208900_B16","first-page":"1050","article-title":"Development of unified lab test result master for multiple facilities","volume":"216","author":"Kume","year":"2015","journal-title":"Stud Health Technol Inform"},{"key":"2022031309340208900_B17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","article-title":"Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates","volume":"56","author":"Horio","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"2022031309340208900_B18","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1001\/archinte.168.20.2212","article-title":"Rapid kidney function decline and mortality risk in older adults","volume":"168","author":"Rifkin","year":"2008","journal-title":"Arch Intern Med"},{"key":"2022031309340208900_B19","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/sim.4200","article-title":"Comparing paired vs non-paired statistical methods of analyses when making inferences about absolute risk reductions in propensity-score matched samples","volume":"30","author":"Austin","year":"2011","journal-title":"Stat Med"},{"key":"2022031309340208900_B20","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2022031309340208900_B21","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/sim.1903","article-title":"Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study","volume":"23","author":"Lunceford","year":"2004","journal-title":"Stat Med"},{"key":"2022031309340208900_B22","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2337\/dc09-1098","article-title":"Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study","volume":"33","author":"Molitch","year":"2010","journal-title":"Diabetes Care"},{"key":"2022031309340208900_B23","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1001\/jama.289.24.3273","article-title":"Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus","volume":"289","author":"Kramer","year":"2003","journal-title":"JAMA"},{"key":"2022031309340208900_B24","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/jdi.12977","article-title":"Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014","volume":"10","author":"Kume","year":"2019","journal-title":"J Diabetes Investig"},{"key":"2022031309340208900_B25","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1681\/ASN.2008121270","article-title":"Albuminuria and kidney function independently predict cardio vascular and renal outcomes in diabetes","volume":"20","author":"Ninomiya","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022031309340208900_B26","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2337\/dc07-0140","article-title":"Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group","volume":"30","author":"Rigalleau","year":"2007","journal-title":"Diabetes Care"},{"key":"2022031309340208900_B27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.semnephrol.2007.01.012","article-title":"Histopathology of diabetic nephropathy","volume":"27","author":"Fioretto","year":"2007","journal-title":"Semin Nephrol"},{"key":"2022031309340208900_B28","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.2337\/dc13-0298","article-title":"Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy","volume":"36","author":"Shimizu","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031309340208900_B29","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031309340208900_B30","doi-asserted-by":"crossref","first-page":"e001157","DOI":"10.1136\/bmjdrc-2019-001157","article-title":"Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy","volume":"8","author":"Furuichi","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2022031309340208900_B31","doi-asserted-by":"crossref","first-page":"e016976","DOI":"10.1161\/JAHA.120.016976","article-title":"Short-term changes in albuminuria and risk of cardiovascular and renal outcomes in type 2 diabetes mellitus: a post hoc analysis of the EMPA-REG OUTCOME trial","volume":"9","author":"Waijer","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2022031309340208900_B32","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"2022031309340208900_B33","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2215\/CJN.03250807","article-title":"Slowing nephropathy progression: focus on proteinuria reduction","volume":"3","author":"Bakris","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022031309340208900_B34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.diabet.2016.12.010","article-title":"Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME","volume":"43","author":"Scheen","year":"2017","journal-title":"Diabetes Metab"},{"key":"2022031309340208900_B35","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"2022031309340208900_B36","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1111\/dom.14415","article-title":"Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: a subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia","volume":"23","author":"Ji","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2022031309340208900_B37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12882-015-0012-x","article-title":"Routine serum creatinine measure ments: how well do we perform?","volume":"16","author":"Hoste","year":"2015","journal-title":"BMC Nephrol"},{"key":"2022031309340208900_B38","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/0004563216664541","article-title":"Post-standardization of routine creatinine assays: are they suitable for clinical applications","volume":"54","author":"Jassam","year":"2017","journal-title":"Ann Clin Biochem"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/11\/2542\/631709\/dc211081.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/44\/11\/2542\/631709\/dc211081.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T06:44:28Z","timestamp":1647153868000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/44\/11\/2542\/138505\/Kidney-Outcomes-Associated-With-SGLT2-Inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,10,18]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc21-1081","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}